Tech Company Financing Transactions
AstriVax Funding Round
On 8/25/2022, AstriVax landed $29.9 million in Seed funding from Fund+, V-Bio Ventures and Ackermans & Van Haaren.
Transaction Overview
Company Name
Announced On
8/25/2022
Transaction Type
Venture Equity
Amount
$29,900,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to bring their first thermostable yellow fever vaccine to the clinical development stage and to further develop their pipeline vaccine candidates -- one to prevent rabies and one to treat chronic hepatitis B.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Ambachtenlaan 1
Heverlee, Leuven, 3001
Belgium
Heverlee, Leuven, 3001
Belgium
Phone
Undisclosed
Website
Email Address
Overview
Starting from validated targets, fast forward clinical development of game-changing vaccines. Addressing major challenges in vaccinology by creating vaccines that are thermostable and offer a durable and polyfunctional protection. Build a diverse vaccine pipeline while targeting initial clinical validation of the platform technology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Hanne Callewaert
Browse more venture capital transactions:
Prev: 8/25/2022: Landing Platforms venture capital transaction
Next: 8/25/2022: Zumper venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC transactions on this site are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs